• Category of evidence -Ia -Evidence from meta-analysis of randomized controlled trials -Ib -Evidence from at least 1 randomized controlled trial -IIa -Evidence from at least 1 controlled study without randomization -IIb -Evidence from at least 1 other type of quasiexperimental study -III -Evidence from nonexperimental descriptive studies, such as comparative studies -IV -Evidence from expert committee reports, opinions or clinical experience of respected authorities or both • Strength of recommendation -A -Directly based on category I evidence -B -Directly based on category II evidence or extrapolated recommendation from category I evidence -C -Directly based on category III evidence or extrapolated recommendation from category I or II evidence -D -Directly based on category IV evidence or extrapolated recommendation from category I, II, or III evidence -LB-Laboratory based -NR -Not rated Global variations in prevalence of eczema symptoms in children from ISAAC Phase 3 Lancet 1998; 351:1225; Odhiambo JA, et al. J Allergy Clin Immunol 2009; 124 Developed and developing countries Moving from reactive to proactive therapy 
International consensus on allergy immunotherapy
• Controversy about potential role of AIT as a therapeutic intervention for patients with AD and aeroallergen sensitivity • Large dose-finding phase II study in HDM-sensitized patients with AD showed significant SCORAD decrease after 8 weeks with effect maintained over 1 year, including lower steroid use • Recent meta-analysis proved moderate-level evidence of efficacy.
However, largest prospective placebo-controlled study included in this meta-analysis showed efficacy only in severely affected patients (SCORAD score >50) • Recent systematic review with Grading of Recommendations Assessment, Development and Evaluation system reported improvement in clinical symptoms with serious methodological shortcomings noted • Only SLIT study performed with HDM allergens in children with AD described a positive outcome only in those with mild-to-moderate AD Interventional studies in AD using biologics Howell MD, et al. Allergy 2015; 70:887 The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization • 42% of eligible families agreed to be randomized into the trial. All participating families in the intervention arm found the intervention acceptable. • A statistically significant protective effect was found with use of daily emollient on cumulative incidence of AD with a relative risk reduction of 50% (relative risk, 0.50; 95% CI, 0.28-0.9; P = .017) • No emollient-related adverse events and no differences in adverse events between groups • Emollient therapy from birth represents a feasible, safe, and effective approach for AD prevention Simpson EL, et al. J Allergy Clin Immunol 2014; 134:818-23 Application of moisturizer to neonates prevents development of atopic dermatitis • Prospective, randomized controlled trial to investigate whether protecting skin barrier with daily moisturizer for first 32 wks of life to 59/118 high risk neonates (based on having a parent or sibling with AD) prevents development of AD and allergic sensitization • 32% fewer neonates in moisturizer group had AD/eczema by week 32 than controls (P = .012) -No significant effect of moisturizer on allergic sensitization (based on sIgE egg white) although sensitization rate significantly higher in infants who had AD/eczema (OR, 2.86; 95% CI, 1.22-6.73)
• Daily moisturizer during the first 32 wks of life reduces risk of AD/eczema in infants Horimukai K, et al. J Allergy Clin Immunol 2014; 134:824-30 
